WuXi AppTec Co., Ltd.

603259

CNE1000031K4

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. Other stock markets 05/12/2025			5-day change	1st Jan Change
90.40 ^CNY	+0.90%		-1.95%	+64.24%

28/11	Traders Await Fresh Catalysts; Asian Stock Markets Churn	MT
28/11	Nomura Adjusts WuXi AppTec's Price Target to HK$132.8 From HK$130.63, Keeps at Buy	MT

Wuxi Apptec Q1 Net Profit Up 89.1% Y/Y

Published on 04/28/2025 at 02:39 pm IST

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about WuXi AppTec Co., Ltd.

28/11	Traders Await Fresh Catalysts; Asian Stock Markets Churn	MT
28/11	Nomura Adjusts WuXi AppTec's Price Target to HK$132.8 From HK$130.63, Keeps at Buy	MT
28/11	Nomura Adjusts WuXi AppTec's Price Target to 120.85 Yuan From 118.83 Yuan, Keeps at Buy	MT
27/11	Pentagon Cites Eight Chinese Companies for Military Aid	MT
10/11	BlackRock's long position in H-shares of Wuxi Apptec increases to 5.48% on Nov 5 - HKEX	RE
29/10	Wuxi Apptec's shareholders to cut 2% A-shares	RE
28/10	Nomura Adjusts WuXi AppTec's Price Target to HK$130.63 From HK$102.77, Keeps at Buy	MT
28/10	Nomura Adjusts WuXi AppTec's Price Target to 118.83 Yuan From 93.49 Yuan, Keeps at Buy	MT
28/10	Neom signs strategic MoU with Wuxi Apptec to advance Saudi's biotechnology sector	RE
28/10	Wuxi Apptec Looks to Extend CRDMO Platform to Saudi Arabia as It Signs Strategic Mous with Neom and Ministry of Health	CI
27/10	Chinese Pharma Firm WuXi AppTec Shares Rise After Strong Results, Guidance Raise	DJ
27/10	WuXi AppTec Books 53% Higher Profit in Q3; Agrees to Sell Two Units to Hillhouse Investment	MT
26/10	WuXi AppTec Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
26/10	WuXi AppTec's unit plans asset sales	RE
26/10	WuXi AppTec Co., Ltd. Raises Earnings Guidance for They Full Year 2025	CI
26/10	Wuxi Apptec's Q3 net profit up 53.3% Y/Y	RE
22/10	BlackRock Inc's long position in H-shares of Wuxi Apptec decreases to 4.50% on Oct 16 from 5.15% - HKEX	RE
17/10	Shandong Buchang Pharmaceuticals Unit Signs 11-Million-Yuan Technical Service Contract	MT
17/10	I-Mab Announces Chief Financial Officer Changes, Effective October 16, 2025	CI
15/10	JPMorgan's long position in H-shares of Wuxi Apptec decreases to 5.59% on Oct 10, HKEX filing shows	RE
13/10	WuXi AppTec Fully Converts $500 Million Bonds; Shares Fall 8%	MT
10/10	WuXi AppTec Offloads Further Stake in WuXi XDC Cayman	MT
09/10	Wuxi Apptec signs disposal deal for HK$2.346 billion	RE
08/10	UBS Group AG's long position in H-shares of Wuxi Apptec decreases to 3.98% on Sept 30 from 5.05%, HKEX shows	RE
06/10	UBS Group AG's long position in H-shares of Wuxi Apptec increases to 5.21% on Sept 29 from 3.62% - HKEX	RE

WuXi AppTec Co., Ltd. specializes in providing a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and biotech industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. Net sales break down by activity as follows: - laboratory services (60.9%): small molecules discovery services, bioanalytical services, medical devices safety testing services, comprehensive manufacturing and testing services for cell and gene therapies, etc.; - CMO and CDMO services (31.9%): development of manufacturing processes, production of advanced intermediates and active pharmaceutical ingredients, formulation development and dosage drug product manufacturing, for preclinical and clinical trials, new drug application, and commercial supply of chemical drugs, etc.; - clinical research services (7.1%): project planning, clinical operation and monitoring and managements of phase I-IV clinical trials, medical device trials, etc.; - other (0.1%). Net sales are distributed geographically as follows: China (25.1%), Asia (4.1%), the United States (53.6%), Europe (16%) and other (1.2%) .

Employees

39,414

Sector

Biotechnology & Medical Research

Calendar

23/03 - Q4 2025 Earnings Release (Projected)

More about the company